We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Glucose Monitoring Devices Help Reduce Long-Term Risks of Diabetes

By HospiMedica International staff writers
Posted on 08 Jun 2009
People with type 1 diabetes who have already been successful in achieving recommended blood sugar goals can further benefit from using continuous glucose monitoring (CGM) devices, according to a new study.

Researchers at the Juvenile Diabetes Research Foundation (New York, NY, USA) conducted a randomized and controlled trial involving 129 adults and children ranging from 8 to 69 years of age at ten different sites, and coordinated by the Jaeb Center for Health Research (Tampa, FL, USA). More...
All participants had good diabetes control when they enrolled in the trial, and were randomly assigned to either a group that used CGM devices or one using standard finger-stick glucose testing for 26 weeks. The main study outcomes were time with glucose level lower than 70 mg/dL, severe hypoglycemic events, and glycated hemoglobin (HbA1c) level, a good measure of long-term blood sugar control.

The researchers found that for the people using CGM devices, the time the blood sugar level was below 70 mg/dL decreased by 37 minutes a day; this compared with a decrease in the control group of only 5 minutes a day. The people in the CGM group spent almost two hours more time per day in the target blood sugar range of 71 to 180 mg/dL compared with the control group, and about half an hour less time per day with glucose values in the potentially dangerous hypoglycemia range. A number of other significant benefits were demonstrated, including an improvement in HbA1c of more than 0.3% (31% in the CGM group versus 5% in the control group); fewer worsening of HbA1c greater than 0.3% (28% versus 52%); more CGM users had a HbA1c level below 7% at 26 weeks (88% versus 63%); and more people in the CGM group than the control group had a decrease in HbA1c of more than 0.3% without experiencing a severe hypoglycemic event (28% versus 5%). Encouragingly, similar beneficial results were seen in children, adolescents, and adults, spanning all ages. The study was published online on May 28, 2009, in the journal Diabetes Care.

"The research suggests that CGM devices helped people who were already doing an excellent job of managing their diabetes continue to do so,” said lead author Bruce Bode, M.D., of the Atlanta Diabetes Associates (GA, USA). "These trials are showing that CGM not only helps people get into control, which can have a significant positive impact on lowering the risk of complications, but it enables them to stay in control without increasing the near-term risk of hypoglycemia. That's terrific news for people with diabetes and their families.”

Diabetics try to maintain their blood sugar levels between 70 mg/dL and 180 mg/dL. If blood sugar levels are very low, people can become confused, lethargic, and even slip into a coma or die; conversely, very high blood sugars can also be dangerous. Long-term lack of control increases the risk of developing devastating complications, including eye, kidney, nerve, and heart disease. HbA1c standards of good control are generally below 7% for adults and below 7.5% to 8% for children, depending on age. Every one-point reduction in HbA1c reduces the risk of long-term complications by approximately 40%.

Reletaed Links:
Juvenile Diabetes Research Foundation
Jaeb Center for Health Research
Atlanta Diabetes Associates



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.